Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 1:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Liking Clear all
Not listed Phase 4 Interventional

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

NCT03424733
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Plegridy, Prednisone, Tylenol Pill
Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

NCT02768805
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 64 Years
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
Hollywood, Florida • South Miami, Florida • Endwell, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Food and Fitness With Medicine (FFWM)

NCT07027995
View directory record Official record
Conditions
Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions
Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Columbus, Ohio • Upper Arlington, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Phase 2 Interventional

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382
View directory record Official record
Conditions
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Collecting Duct Carcinoma, Invasive Bladder Giant Cell Urothelial Carcinoma, Invasive Bladder Lymphoepithelioma-Like Carcinoma, Invasive Bladder Nested Urothelial Carcinoma, Invasive Bladder Plasmacytoid Urothelial Carcinoma, Invasive Bladder Sarcomatoid Urothelial Carcinoma, Invasive Bladder Urothelial Carcinoma, Kidney Medullary Carcinoma, Large Cell Neuroendocrine Carcinoma, Malignant Testicular Leydig Cell Tumor, Malignant Testicular Sertoli Cell Tumor, Metastatic Bladder Carcinoma, Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma, Metastatic Bladder Giant Cell Urothelial Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Lipid-Rich Urothelial Carcinoma, Metastatic Bladder Micropapillary Urothelial Carcinoma, Metastatic Bladder Plasmacytoid Urothelial Carcinoma, Metastatic Bladder Sarcomatoid Urothelial Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Malignant Genitourinary System Neoplasm, Metastatic Papillary Renal Cell Carcinoma, Metastatic Penile Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Urethral Carcinoma, Papillary Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Bladder Cancer AJCC v8, Stage IV Penile Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Urachal Adenocarcinoma, Urethral Clear Cell Adenocarcinoma
Interventions
Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
578
States / cities
Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Not applicable Interventional

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Open Wounds

NCT07041177
View directory record Official record
Conditions
Open Wound
Interventions
NeoThelium FT
Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hammond, Louisiana
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers

NCT06550596
View directory record Official record
Conditions
Diabetic Foot, Ulcer Foot, Foot Ulcer, Diabetic Foot Ulcer
Interventions
Standard of Care, Axolotl DualGraft + SOC
Other
Lead sponsor
Axolotl Biologix
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Prospective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Venous Leg Ulcers

NCT07061613
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
NeoThelium FT (HCT/P 361)
Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Metairie, Louisiana • Slidell, Louisiana
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

NCT02475278
View directory record Official record
Conditions
Norovirus, Healthy Participants
Interventions
NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs

NCT06674980
View directory record Official record
Conditions
Pathologic Processes, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Disease, Diabetic Angiopathies, Vascular Diseases, Cardiovascular Diseases, Leg Ulcer, Skin Ulcer, Skin Diseases, Diabetes Complications, Diabetic Neuropathies, Foot Diseases, Diabetic Foot, Foot Ulcer, Diabetes Mellitus, Type 2, Ulcer, Foot Ulcer Unhealed
Interventions
Standard of Care - DFU, AM/Single - DFU, AM/Double - DFU, Standard of Care - VLU, AM/Single - VLU, AM/Double - VLU
Other
Lead sponsor
C5 Biomedical
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Metairie, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

NCT00892736
View directory record Official record
Conditions
Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 1 Interventional

Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma

NCT02010606
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, Astrocytoma, Brain Tumor
Interventions
Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy, Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Jun 10, 2026, 1:23 AM EDT
Terminated Phase 1 Interventional

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

NCT03301896
View directory record Official record
Conditions
Solid Tumors
Interventions
LHC165, PDR001
Drug · Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

NCT03039790
View directory record Official record
Conditions
Healthy Volunteers, Norovirus
Interventions
NoV Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Jun 10, 2026, 1:23 AM EDT
Completed No phase listed Observational

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

NCT05526157
View directory record Official record
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jun 10, 2026, 1:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine

NCT03776994
View directory record Official record
Conditions
Encephalitis, Encephalitis, Viral, Infectious Encephalitis, Virus Diseases, Encephalomyelitis, Venezuelan Equine, Brain Diseases, Central Nervous System Diseases, Central Nervous System Viral Diseases, Alphavirus Infections, Togaviridae Infections, RNA Virus Infections, Central Nervous System Infections, Encephalomyelitis, Physiological Effects of Drugs, Vaccines, Encephalomyelitis, Equine, Nervous System Diseases
Interventions
Vaccinations on Day 0, Day 28, and Day 140
Biological
Lead sponsor
SRI International
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plymouth, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults

NCT02669121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NoV Placebo-matching Saline, NoV GI.1/GII.4 Bivalent VLP Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,748 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Great Lakes, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Jun 10, 2026, 1:23 AM EDT
Recruiting Not applicable Interventional

Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers

NCT06938685
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Standard of Care, NeoThelium FT
Other
Lead sponsor
NuScience Medical Biologics, LLC
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
8
States / cities
Alexandria, Louisiana • Franklinton, Louisiana • Hammond, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Interventions
CFI-400945, Azacitidine
Drug
Lead sponsor
Treadwell Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

NCT04392011
View directory record Official record
Conditions
Interaction Drug Food
Interventions
Midazolam HCl, Dextromethorphan HBr, Kratom
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

NCT03110770
View directory record Official record
Conditions
Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions
VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
15 Years to 35 Years
Enrollment
2,428 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Miami, Florida • Edinburg, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Jun 10, 2026, 1:23 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

NCT03793478
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Month to 21 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults

NCT01892189
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 10, 2026, 1:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults

NCT01991587
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Low dose of quadrivalent VLP vaccine, Medium dose of quadrivalent VLP vaccine, High dose of quadrivalent VLP vaccine, Placebo
Biological
Lead sponsor
Medicago
Industry
Eligibility
18 Years to 49 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2020 · Synced Jun 10, 2026, 1:23 AM EDT